Cargando…

ATTR Epidemiology, Genetics, and Prognostic Factors

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed disease and an underestimated cause of both heart failure and conduction abnormalities. It is characterized by pathologic accumulation of extracellular protein arising from unstable transthyretin (TTR) tetramers, which dissociate in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obi, Chukwuemeka A., Mostertz, William C., Griffin, Jan M., Judge, Daniel P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Houston Methodist DeBakey Heart & Vascular Center 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932385/ https://www.ncbi.nlm.nih.gov/pubmed/35414855 http://dx.doi.org/10.14797/mdcvj.1066

Ejemplares similares

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots
por: Auer-Grumbach, Michaela, et al.
Publicado: (2020)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
por: Nativi‐Nicolau, Jose, et al.
Publicado: (2021)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review
por: Griffin, Jan M., et al.
Publicado: (2021)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Imaging cardiac ATTR amyloid
por: Hawkins, Philip N
Publicado: (2015)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy
por: Panayiotou, E., et al.
Publicado: (2016)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Attred: Attribute Based Resource Discovery for IoT †
por: Kamel, Mohammed B. M., et al.
Publicado: (2021)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
por: Rintell, David, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Glavonoid, a possible supplement for prevention of ATTR amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2021)

Retiring LevelDBs with the new FST attr backend
por: Lekshmanan, Abhishek
Publicado: (2023)

Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2019)

Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system
por: Conceição, Isabel
Publicado: (2019)

ATTR Cardiomyopathy Meets Multiple Myeloma: The Importance of Cardiac Biopsy
por: Kanelidis, Anthony J., et al.
Publicado: (2021)

Unravelling the epidemiology of late-onset and asymptomatic carriers of FAP ATTR V30M in a Portuguese population
por: Lemos, Carolina, et al.
Publicado: (2015)

Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus
por: Chander Mohan, Jagdish, et al.
Publicado: (2022)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)
por: Ferreira, Natália
Publicado: (2015)

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis
por: Lobato, Luisa
Publicado: (2015)

TUDCA as an autophagic modulator of ATTR V30M Amyloidosis
por: Teixeira, Cristina, et al.
Publicado: (2015)

The role of complement in ATTR amyloidosis: a new therapeutic avenue?
por: Panayiotou, Elena, et al.
Publicado: (2015)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

Cellular environment of TTR deposits in an animal model of ATTR—Cardiomyopathy
por: Teixeira, Cristina, et al.
Publicado: (2023)

Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK
por: Gillmore, Julian D., et al.
Publicado: (2022)

Early Treatment of Cardiac ATTR: “To Remove the Weeds, You Have to Get the Roots”
por: Lenihan, Daniel, et al.
Publicado: (2022)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a8heugt8rgghtt0a8n3u4nc44d